H, Norasakkunkit V. Individual and collective processes in the construction of the self: self-enhancement in the United States and self-criticism in Japan. J Pers Soc Psychol. 1997; 72(6): 1245–67

87

https://www.thelancet.com/commissions/global-mental-health

88

https://www.who.int/news-room/fact-sheets/detail/depression

89

DALY, disability-adjusted life year, – потенциальный год жизни, утраченный из-за преждевременной смерти, инвалидности или слабого здоровья, рассчитывается, как сумма двух слагаемых: YLL (Years Life Lost – потери, обусловленные смертностью) и YLD (Years Lost due to Disability – потери здоровья, обусловленные нетрудоспособностью). Global Health Estimates 2019: 20 Leading Causes of DALY globally, 2019 and 2000.

90

Merikangas KR, He J, Burstein M, et al. Lifetime Prevalence of Mental Disorders in US Adolescents: Results from the National Comorbidity Study-Adolescent Supplement (NCS-A). Journal of the American Academy of Child and Adolescent Psychiatry. 2010; 49(10): 980–989. doi:10.1016/j.jaac.2010.05.017

91

Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U. S. Department of Health and Human Services; 2014

92

Akinbami LJ, Moorman JE, Bailey C, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001–2010. NCHS data brief, no 94. Hyattsville, MD: National Center for Health Statistics. 2012

93

Prevalence of mood disorders in the rural population of Udmurtia. Pakriev, Acta Psychiatr Scand. 1998 Mar; 97(3): 169–74

94

Simon GE, VonKorff M. Recognition, management, and outcomes of depression in primary care. Arch Fam Med 1995; 4: 99–105

95

МКБ-11.

96

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association, 1994

97

World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992

98

Tsuang MT, Taylor L, Faraone SV. An overview of the genetics of psychotic mood disorders. J Psychiatr Res. 2004; 38: 3–15

99

Nutt DJ (2008). "Relationship of neurotransmitters to the symptoms of major depressive disorder". Journal of Clinical Psychiatry. 69 Suppl E1: 4–7

100

Merzenich MM, Nelson RJ, Stryker MP, Cynader MS, Schoppmann A, Zook JM. Somatosensory cortical map changes following digit amputation in adult monkeys. J Comp Neurol. 1984; 224(4): 591–605.

101

Davidson RJ, McEwen BS. Social influences on neuroplasticity: Stress and interventions to promote well-being. Nature neuroscience. 2012; 15(5): 689–695. doi: 10.1038/nn. 3093

102

Castrén E, Rantamäki T. Neurotrophins in depression and antidepressant effects. Novartis Found Symp. 2008; 289: 43–52

103

Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol. 2010; 70(5): 289–97

104

Goldman-Rakic PS (October 1996). The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 351(1346): 1445–53

105

X. T. Wang and Robert D. Dvorak. Sweet Future: Fluctuating Blood Glucose Levels Affect Future Discounting. Psychological Science, 21, 183–188

106

Maes M. "Functional" or "psychosomatic" symptoms, e. g. a flu-like malaise, aches and pain and fatigue, are major features of major and in particular of melancholic depression. Neuro Endocrinol Lett. 2009; 30(5): 564–73

107

Ryan KA, Dawson EL, Kassel MT, et al. Shared dimensions of performance and activation dysfunction in cognitive control in females with mood disorders. Brain. 2015; 138(Pt 5): 1424–34

108

Mackin P, Young AH, The Role of Cortisol and Depression: Exploring New Opportunities for Treatments, Psychiatric Times, 2004; 21: 92–5

109

Касьянов Е. Д., Мазо Г. Э. Функционирование гипоталамо-гипофизарно-надпочечниковой оси при депрессии: актуальное состояние проблемы. // Психическое здоровье. 2017. № 8. С. 27–34.

110

Herbert J. Cortisol and depression: three questions for psychiatry. Psychol Med. 2013; 43(3): 449–69.

111

Sapolsky RM. Depression, antidepressants, and the shrinking hippocampus. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(22): 12320–12322

112

D'Mello, C., and Swain, M. G. (2017). Immune-to-brain communication pathways in inflammation-associated sickness and depression. Curr.

113

https://www.nature.com/articles/s41398–021–01302–0?utm_medium=affiliate&utm_source=commission_junction&utm_campaign=3_nsn6445_deeplink_PID100029727&utm_content=deeplink.

114

Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010. Hay PJ, ed. PLoS Medicine. 2013; 10(11): e1001547

115

Соломон Э. Демон полуденный: Анатомия депрессии. – М.: Добрая книга, 2004

116

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0169764

117

Lorant V, Deliege D, Eaton W, Robert A, Philippot P, Ansseau M. Socioeconomic inequalities in depression: a meta-analysis. Am J Epidemiol. 2003;157:98–112.

118

Jonassen R, Chelnokova O, Harmer C, Leknes S, Landrø NI. A single dose of antidepressant alters eye-gaze patterns across face stimuli in healthy women. Psychopharmacology (Berl). 2015; 232(5): 953–8.

119

Selikoff IJ, Robitzek EH. Tuberculosis chemotherapy with hydrazine derivatives of isonicotinic acid. Dis Chest. 1952; 21(4): 385–438

120

Burn JH. The Antihistamine Compounds. British Medical Journal. 1958; 2(5100): 845–846

121

Pletscher A. The discovery of antidepressants: a winding path. Experientia. 1991; 47(1): 4–8

122

Fagius J, Osterman PO, Sidén A, Wiholm